Beun G D, van de Velde C J, Fleuren G J
Dept of Surgery, Academic Hospital Leiden, The Netherlands.
Immunol Today. 1994 Jan;15(1):11-5. doi: 10.1016/0167-5699(94)90019-1.
In development of strategies for immunotherapy of cancer a new emphasis is emerging, termed T-cell retargeting, which involves artificial redirection of cytotoxic T lymphocytes (CTL) against cancer cells, using bispecific reagents. In this article, Gideon Beun, Cornelis van de Velde and Gert Jan Fleuren evaluate this potential strategy for cellular immunotherapy, and propose how the gap between in vitro results and clinical application might be bridged.
在癌症免疫治疗策略的发展中，一种新的重点正在出现，即所谓的T细胞重定向，它涉及使用双特异性试剂将细胞毒性T淋巴细胞（CTL）人工重定向至癌细胞。在本文中，吉迪恩·博恩、科内利斯·范德维尔德和格特·扬·弗勒伦评估了这种细胞免疫治疗的潜在策略，并提出了如何弥合体外研究结果与临床应用之间差距的建议。
